// App-Quantinova.ai

1931 : MiR182 mediated control over myeloid differentiation provides novel mechanism of Imatinib resistance in chronic myeloid leukemia

Researchers

Presenter

  • Deepak Arya

Principal Investigators

  • P. Sasikala

  • Shang Li

  • Dasaradhi Palakodeti

  • Cecil Ross

  • Sudhir Krishna

Medical Centers

  • National Centre for Biological Sciences, Bangalore, India

  • Duke-NUS, Singapore, Singapore

  • InStem, Bangalore, India

  • St. John's Medical College and Hospitals, Bangalore, India.

Locations

  • India

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Breast cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Breast cancer type 1 susceptibility protein

  • Cluster of Differentiation 34

  • Hes family bHLH transcription factor 1

Drug/Treatment

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved